BIOD Biodel Inc. featured news, full reports, and detailed charts
Biodel Inc. (BIOD) Wrap Up:
We are a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for endocrine disorders such as diabetes and osteoporosis, which may be safer, more effective and convenient. We develop our product candidates by applying our proprietary formulation technologies to existing drugs in order to improve their therapeutic results. Our initial development efforts are focused on peptide hormones. We have two insulin product candidates currently in clinical trials for the treatment of diabetes. Additionally, we have two preclinical product candidates for the treatment of osteoporosis, one with parathyroid hormone 1-34 and the other with salmon calcitonin. Our most advanced product candidate is VIAjecttm, a proprietary injectable formulation of recombinant human insulin designed to be absorbed into the blood faster than currently marketed rapid-acting insulin products. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2007%2f12%2f21%2f0000950123-07-016969.html#FIS_BUSINESS"Biodel Inc. (BIOD:NASDAQ)
Snapshot of Biodel Inc. (BIOD)
|
OPEN
$3.72
|
PREVIOUS CLOSE
$3.75
|
|
|
DAY HIGH
$4.29
|
DAY LOW
$3.64
|
|
|
52 WEEK HIGH
06/12/09 - $6.02
|
52 WEEK LOW
12/12/08 - $2.19
|
|
|
MARKET CAP
98.8M
|
AVERAGE VOLUME 3 mo
47.9K
|
|
|
DILUTED EPS TTM
$-1.93
|
SHARES OUTSTANDING
23.8M
|
|
|
BIOD Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
BIOD Top Compensated Officers
Executives, Board Directors
Key developments for Biodel Inc. (BIOD)
To present a corporate update
To present a corporate update
Biodel Inc. reported consolidated financial results for the third quarter and nine months ended June 30, 2009. For the quarter, the company reported a net loss of $11.1 million, or $0.47 per share, compared to a net loss of $10.1 million, or $0.43 per share, for the comparable period in the prior year. Operating loss before tax for the quarter was $10.629 million versus $10.655 million for the same quarter last year. For the nine months, the company reported a net loss of $32.8 million, or $1.38 per share, compared to a net loss of $30.696 million, or $1.40 per share, for the comparable period in the prior year. Operating loss before tax for the nine months was $32.421 million versus $31.187 million for the same period last year.
BIOD Competitors
| Company | Last | Change |
| Apollo Consolidated Limited | A$0.01 AUD | -0.002 |
| Aradigm Corp | $0.16 USD | +0.005 |
| Emisphere Technologies | $0.67 USD | 0.00 |
| Generex Biotechnology Corp | $0.50 USD | -0.01 |
| MannKind Corp | $6.88 USD | -0.06 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | BIOD | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 1.5x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
|
BIOD |
||
BIOD transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||